Name | Diflunisal |
Description | Diflunisal (Dolobid) is a cyclooxygenase (COX) Inhibitor, used as an anti-inflammatory analgesic. |
Cell Research | HEK293T cells are transfected with expression vectors for WT p300 or catalitycally inactive mutant. 24 hr after transfection, cells are treated with diflunisal as indicated for 24 hr. H2B acetylation is measured by Western Blot using specified antibodies. Experiments are repeated four times. (Only for Reference) |
In vitro | Diflunisal, an FDA-approved drug containing a salicylic acid substructure, inhibited CBP/p300 more potently than salicylate. Diflunisal exhibits anti-tumor activity against a specific leukemia carrying a t(8;21) translocation, a tumor previously reported to be dependent on p300 in vitro and in vivo[2]. |
In vivo | Diflunisal-mediated kinetic stabilization of TTR(Rate-limiting transthyretin) should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically[3]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (199.84 mM) Ethanol : 20 mg/mL (79.94 mM)
|
Keywords | Cyclooxygenase | MK 647 | COX | Diflunisal | Inhibitor | MK647 | inhibit |
Inhibitors Related | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Curcumin | Diclofenac Potassium | Paradol | Indomethacin sodium hydrate | Naphthol AS-E | Revaprazan hydrochloride |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |